1. Introduction
===============

Infertility is the inability of a couple to conceive pregnancy after 1 year of unprotected, regular sexual intercourse and affects approximately 10% to 20% of couples.^\[[@R1],[@R2]\]^ Among them, approximately 50% of the cases are associated with male factors.^\[[@R3]\]^ It is thought that lifestyle factors and environmental factors such as cigarette, smoking, and exposure to certain chemicals, are potential causes of male infertility.^\[[@R4],[@R5]\]^ In addition, genetic factors, such as chromosomal aberrations, gene mutations, and polymorphisms, can also be associated with male infertility.^\[[@R6]--[@R8]\]^ Several studies suggest the *CYP1A1* gene as a candidate gene for male infertility.^\[[@R9],[@R10]\]^

*Cytochrome* P4501A1 gene, located on chromosome 15q22-q24, is 5987-bp long and encodes a 512 amino acid protein.^\[[@R11],[@R12]\]^ CYP1A1, a member of the CYP1 family, involved in the metabolism of a vast number of xenobiotics and endogenous substrates.^\[[@R13]\]^ The disturbed testicular expression of CYP1A1 is responsible for producing hydroxyestradiols and/or methoxyestradiols, and the increased intratesticular hydroxyestradiols and methoxyestradiols concentrations could elicit an impaired Sertoli cell function, this could ultimately lead to male infertility.^\[[@R14]\]^ Several single-nucleotide polymorphisms (SNPs) of *Cytochrome* P4501A1 gene have been identified, including T3801C, T3205C, A2455G.^\[[@R13]\]^ Among them, *P4501A1* MspI (3798 T \> C; *CYP1A1*∗2A; rs4646903) polymorphism is one of the most-studied single-nucleotide polymorphism (SNP). Recently, many genetic studies have investigated the association between the *CYP1A1* rs4646903 polymorphism and the risk of male infertility. However, these studies have relatively sample size and the results remain controversial. In 2013, a meta-analysis based on 6 case-control studies including 1060 cases and 1225 controls was conducted, the authors concluded that the *CYP1A1* rs4646903 polymorphism is capable of causing male infertility susceptibility in Asians, but not in Caucasians.^\[[@R15]\]^ In 2014, a meta-analysis conducted by Luo et al^\[[@R16]\]^ demonstrated that the *CYP1A1* rs4646903 polymorphism was associated with male infertility in overall population, however, no association was observed between *CYP1A1* rs4646903 polymorphism and male infertility in both Asians and Caucasians. In addition, several novel related studies of male infertility risk have since been published. Therefore, in the present study, we performed an updated meta-analysis based on 10 studies of the *CYP1A1* rs4646903 polymorphism (3028 cases and 3258 controls) to elucidate the relationship between the *CYP1A1* rs4646903 polymorphism and male infertility risk.

2. Methods
==========

2.1. Search strategy
--------------------

To assess the complete evidence of an association between the *CYP1A1* rs4646903 polymorphism and male infertility, we performed the present comprehensive meta-analysis of published studies. Medline, Web of science, Embase, CBM, CNKI, WanFang, and VIP databases were searched for relevant articles up to June 30, 2018. The following search terms and keywords were used: "*CYP1A1* gene" or "Cytochrome P450 1A1 gene," and "SNP" or "polymorphism" or "mutation" or "variant" and "male infertility". References of all relevant studies were reviewed to obtain additional references. All analyses were based on previous published studies, thus no ethical approval and patient consent are required.

2.2. Inclusion and exclusion criteria
-------------------------------------

Studies were considered eligible if they met the following criteria: case-control study; full text of the article was available; available data to estimate an odds ratio (OR) with 95% confidence interval (CI); the genetypes in cases and controls were available. Exclusion criteria included: studies not concerning association between the *CYP1A1* rs4646903 polymorphism and male infertility risk; repeated or overlapping publications; and animal studies, review articles, meta-analysis, and conference abstracts or editorial articles.

2.3. Quality assessment and data extraction
-------------------------------------------

The Newcastle-Ottawa Scale (NOS) was used to assess the quality of included studies by 2 authors.^\[[@R17]\]^ This scale assesses the quality of case-control studies included 3 areas: selection, comparability, and exposure. A star rating system was used to judge methodological quality. Scores range from 0 stars (worst) to 9 stars (best), and studies with a score ≥7 were defined as high quality. Discrepant opinions were resolved by discussion and consensus. Two investigators extracted the data using a standardized data extraction form independently. Discrepancies were resolved by discussion with a third investigator. The following information was extracted from each study: first author, year of publication, sample size, geographical location, genotype frequencies of CYP1A1.

2.4. Statistical analysis
-------------------------

Odds ratios (ORs) with 95% CIs were used to assess the strength of association between *CYP1A1* rs4646903 polymorphism and male infertility risk. The pooled ORs were performed for *CYP1A1* rs4646903 polymorphism under the allele comparison model (C vs T), additive model (CC vs TT), recessive model (CC vs CT+TT), and dominant model (CC+CT vs TT), respectively. The significance of the pooled OR was analyzed by the Z test, and *P* \< .05 was considered statistically significant. The Chi-square-based *Q*-test and *I*^2^ statistics were used to calculated heterogeneity among included studies. The *P* \> .05 for *Q* test or *I*^2^ \< 50% indicated a statistically significant degree of heterogeneity among studies. In contrast, the random-effects model was used. All statistical analyses were performed by using Revman 5.3 and Stata 14.0. Publication bias was investigated with the funnel plot, Begg test, and Egger test. Sensitivity analysis was conducted to assess the stability of the results by sequentially omitted individual studies.

3. Results
==========

3.1. Description of included studies
------------------------------------

A total of 131 studies were retrieved from online databases. Of these, after the first screening, 121 studies were excluded based on inclusion and exclusion criteria. Finally, 10 studies including 3028 cases and 3258 controls were included in this meta-analysis.^\[[@R9],[@R17]--[@R25]\]^ A detailed flow chart of the study selection is shown in Fig. [1](#F1){ref-type="fig"}. The years of publication ranged from 2008 to 2017, and there were 7 studies of Asian descendants and 3 studies of Non-Asian descendants. The Hardy-Weinberg test (HWE) was performed on all of the included studies, and the results showed that the *CYP1A1* rs4646903 gene genotype frequencies of all 10 studies were in HWE in the controls (Table [1](#T1){ref-type="table"}).

![Flowchart showing the study selection.](medi-98-e16543-g001){#F1}

###### 

Characteristics of the studies included in the meta-analysis and their genotype distributions of the *CYP1A1* rs4646903 polymorphism.
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3.2. Meta-analysis of *CYP1A1* rs4646903 polymorphism in male infertility susceptibility
----------------------------------------------------------------------------------------

Ten studies involving a total of 6286 individuals evaluated the influence of the *CYP1A1* gene variant rs4646903 polymorphism on the risk of male infertility. Figures [2](#F2){ref-type="fig"}--[5](#F5){ref-type="fig"} show the meta-analysis results for the allele model, additive model, recessive model, and dominant model, for which the *I*^2^ value was 78%, 69%, 67%, and 75%, respectively. Thus, the random effect model was used to synthesize the data. Overall, pooled risk estimates indicated that *CYP1A1* rs4646903 polymorphism was associated with an increased risk of male infertility (C vs T: OR = 1.42, 95%CI = 1.14--1.76; CC vs TT: OR = 2.13, 95%CI = 1.36--3.34; CC vs CT+TT: OR = 1.96, 95%CI = 1.30--2.95; CC+CT vs TT: OR = 1.51, 95%CI = 1.16--1.97).
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![Forest plot of the studies assessing the association between *CYP1A1* rs4646903 polymorphism and male infertility. (Additive model: CC vs TT).](medi-98-e16543-g004){#F3}
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![Forest plot of the studies assessing the association between *CYP1A1* rs4646903 polymorphism and male infertility. (Recessive model: CC vs CT+TT).](medi-98-e16543-g006){#F5}

Subgroup analysis based on ethnicity indicated that the *CYP1A1* rs4646903 polymorphism was associated with increased susceptibility to male infertility in Asians (C vs T: OR = 1.59, 95%CI = 1.22--2.08; CC vs TT: OR = 2.58, 95%CI = 1.46--4.56; CC vs CT+TT: OR = 2.33, 95%CI = 1.38--3.91; CC+CT vs TT: OR = 1.58, 95%CI = 1.11--2.26), however, no association was found between the *CYP1A1* rs4646903 polymorphism and male infertility risk in Non-Asians (C vs T: OR = 1.01, 95%CI = 0.79--1.30; CC vs TT: OR = 1.22, 95%CI = 0.66--2.25; CC vs CT+TT: OR = 1.15, 95%CI = 0.64--2.05; CC+CT vs TT: OR = 0.98, 95%CI = 0.72--1.34) (Table [2](#T2){ref-type="table"}).
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Meta-analysis of the association of *CYP1A1* rs4646903 polymorphism with male infertility.
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3.3. Publication bias and sensitivity
-------------------------------------

There was no evidence of obvious asymmetry in the funnel plots (Fig. [6](#F6){ref-type="fig"}). The Begg test and Egger test were also performed to access publication bias in the articles included in this meta-analysis. No significant publication bias was observed under all the genetic models, as shown in Fig. [6](#F6){ref-type="fig"} and Table [3](#T3){ref-type="table"}. Sensitivity analyses were conducted to calculate pooled ORs by omitting one study each time. Results showed that no individual study influenced overall pooled ORs (Fig. [7](#F7){ref-type="fig"}), indicating that the results of this meta-analysis are relatively stable.

![Funnel plot for the *CYP1A1* rs4646903 polymorphism and male infertility risk. (A. Allelic model: C vs T; B. additive model: CC vs TT; C. dominant model: CC+CT vs TT; D. recessive model: CC vs CT+TT).](medi-98-e16543-g008){#F6}
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Publication bias test for *CYP1A1* rs4646903 polymorphism.
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![Sensitivity analysis diagram for each study used to assess the relative risk estimates for the *CYP1A1* rs4646903 polymorphism and male infertility in all of the included studies. (A. Allelic model: C vs T; B. additive model: CC vs TT; C. dominant model: CC+CT vs TT; D. recessive model: CC vs CT+TT).](medi-98-e16543-g010){#F7}

4. Discussion
=============

In the present study, significant associations with the risk of male infertility were detected for the *CYP1A1* rs4646903 polymorphism. Further subgroup analyses based on ethnicity of study subjects revealed that genetic variations of *CYP1A1* gene rs4646903 may contribute to susceptibility to male infertility in Asians, but not in Non-Asians.

Cytochrome P4501A1, an important phase I enzyme, plays an essential role in the metabolism of polycyclic aromatic hydrocarbons (PAHs).^\[[@R21],[@R26]\]^ PAHs are able to form DNA adducts once it has been activated to DNA reactive metabolites.^\[[@R27]\]^ DNA adducts could be considered as a sign of severe DNA damage in sperm cells, which played an essential role in meiotic division during spermatogenesis and associated with male infertility.^\[[@R18],[@R28]\]^ It has been suggested that the SNPs of the *CYP1A1* gene could determine the activity and/or inducibility of *CYP1A1*.^\[[@R19],[@R29]\]^ Recent studies have revealed that *CYP1A1* rs4646903 polymorphism was associated with an increased risk of male infertility, but the results of these studies were inconsistent. Lu et al^\[[@R17]\]^ reported that no significant association was detected between *CYP1A1*∗2A polymorphism and male infertility in Chinese population. Similarly, a case-control study conducted by Yarosh et al^\[[@R20]\]^ revealed that *CYP1A1*∗2A polymorphism do not contribute to male infertility of Colombian Caribbean men. However, Flórez et al^\[[@R21]\]^ reported that CC genotype of *CYP1A1* is associated in the pathogenesis of male infertility in Indian population. The difference between the studies could arise from race, geography, or genetic background of the study population. Subsequently, two meta-analysis, included 6 studies involving 1060 cases and 1225 controls, comprehensively evaluated the associations between *CYP1A1* rs4646903 polymorphism and male infertility risk, but there results were still inconsistent.^\[[@R14],[@R15]\]^ This inconsistent result may arise from different search strategies, and the 2 meta-analyses do not include all relevant studies.

In the present study, 10 studies including 3028 cases and 3258 controls were included, the overall results showed that *CYP1A1* rs4646903 polymorphism could increase the risk of male infertility (C vs T: OR = 1.42, 95%CI = 1.14--1.76; CC vs TT: OR = 2.13, 95%CI = 1.36--3.34; CC vs CT+TT: OR = 1.96, 95%CI = 1.30--2.95; CC+CT vs TT: OR = 1.51, 95%CI = 1.16--1.97). It reveals that individuals with the variant C allele may have a higher risk for male infertility than those carrying T homozygote. Nevertheless, in the subgroup analysis of ethnicity, we found that *CYP1A1* rs4646903 polymorphism had an effect on increase in the male infertility risk in Asians, while the susceptibility to male infertility was not observed in Non-Asian population. However, only 3 studies reported the relationship between the *CYP1A1* rs4646903 polymorphism and male infertility risk in Non-Asians and 5 studies for Asian population were included in the present meta-analysis. The sample size was small, thus, studies with larger sample sizes are needed to further investigate the potential relationships of *CYP1A1* rs4646903 polymorphism with male infertility risk.

When interpreting the results of the current study, there are still several limitations should be considered. First, only 10 studies were incorporated in the meta-analysis, the sample size of included published articles was small. Second, subgroup analyses such as by infertility type and source of control group were not performed, due to the lack of information. Third, the effects of gene--gene and gene--environment interactions on male infertility susceptibility were not estimated, as the studies enrolled lacked of information. Finally, our results were based on unadjusted estimates, due to the lack of data of smoking, age, and other environmental exposure factors.

5. Conclusions
==============

This meta-analysis result suggests that the *CYP1A1* rs4646903 polymorphism may increase the risk of male infertility, especially in Asians. However, large sample size, well-designed, and population-based studies are necessary to comprehensively verify the association between *CYP1A1* gene variant rs4646903 polymorphism and male infertility risk.
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